Rigel Pharmaceuticals, Inc. (RIGL)

Compare

17.44

+1.07

+(6.54%)

As of 2:03:25 PM EDT. Market Open.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,350 stock options and restricted stock units to seven non-executive employees vesting over four years w

PR Newswire 5 days ago

RIGL
+6.54%
High Growth Tech Stocks in the US for April 2025

Over the last 7 days, the United States market has dropped 5.6%, yet it remains up by 3.3% over the past year, with earnings projected to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves focusing on companies that can capitalize on robust earnings potential and demonstrate resilience amid recent market fluctuations.

Simply Wall St. 5 days ago

RDVT

CKPT

RIGL
+6.54%
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent litigation related to Rigel's product TAVALISSE® (fostamatinib disodium hexahydrate). The litigation resulted from submission by Annora of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of TAVALISSE

PR Newswire 13 days ago

RIGL
+6.54%
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are

Even though Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) posted strong earnings, investors appeared to be underwhelmed...

Simply Wall St. 25 days ago

RIGL
+6.54%
Rigel Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

Rigel Pharmaceuticals ( NASDAQ:RIGL ) Full Year 2024 Results Key Financial Results Revenue: US$179.3m (up 55% from FY...

Simply Wall St. 29 days ago

RIGL
+6.54%
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.

PR Newswire 30 days ago

RIGL
+6.54%
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders are probably feeling a little disappointed, since its shares...

Simply Wall St. last month

RIGL
+6.54%
Q4 2024 Rigel Pharmaceuticals Inc Earnings Call

Q4 2024 Rigel Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

RIGL
+6.54%
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade

The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

RIGL
+6.54%
Rigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

Rigel Pharmaceuticals Inc (RIGL) reports a 39% revenue increase and its first full year of net income, while expanding its global footprint and development pipeline.

GuruFocus.com last month

RIGL
+6.54%
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

RIGL
+6.54%
Rigel: Q4 Earnings Snapshot

On a per-share basis, the South San Francisco, California-based company said it had net income of 80 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 55 cents per share.

Associated Press Finance last month

RIGL
+6.54%
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP); REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML);

PR Newswire last month

RIGL
+6.54%
Sea Limited to Post Q4 Earnings: What's in Store for the Stock?

SE's fourth-quarter performance is likely to have benefited from strong Shopee and SeaMoney growth. Competition and FX volatility are expected to have hurt profitability.

Zacks last month

SE

RIGL
+6.54%
AUNA
High Growth Tech Stocks In The US Market To Watch

Over the last 7 days, the United States market has dropped 3.6%, yet over the longer term, it has risen by 17% in the last year with earnings forecasted to grow by 14% annually. In light of these conditions, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can capitalize on future earnings growth.

Simply Wall St. last month

COMM

GRND

RIGL
+6.54%
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.

Zacks last month

RIGL
+6.54%
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

PR Newswire last month

RIGL
+6.54%
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.

Zacks last month

RIGL
+6.54%
With 57% ownership of the shares, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is heavily dominated by institutional owners

Key Insights Given the large stake in the stock by institutions, Rigel Pharmaceuticals' stock price might be vulnerable...

Simply Wall St. last month

RIGL
+6.54%
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect?

The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 2 months ago

RIGL
+6.54%

Performance Overview

Return	RIGL	S&P 500 (^GSPC)
YTD	+3.69%	-8.40%
1-Year	+39.52%	+3.40%
3-Year	-43.19%	+20.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

High Growth Tech Stocks in the US for April 2025

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are

Rigel Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Q4 2024 Rigel Pharmaceuticals Inc Earnings Call

Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade

Rigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates

Rigel: Q4 Earnings Snapshot

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Sea Limited to Post Q4 Earnings: What's in Store for the Stock?

High Growth Tech Stocks In The US Market To Watch

Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

With 57% ownership of the shares, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is heavily dominated by institutional owners

Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect?

Performance Overview